Capecitabine ๐
๐ Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), allowing oral administration of a chemotherapy agent usually given intravenously.
Always check the BNF here for up-to-date prescribing advice.
โน๏ธ About
- Check the BNF or equivalent for up-to-date prescribing guidance.
- Not superior in efficacy to IV 5-fluorouracil, but offers convenience of oral delivery.
โ๏ธ Mode of Action
- Capecitabine is a prodrug converted in vivo to 5-fluorouracil (5-FU).
- 5-FU is a pyrimidine analogue that inhibits thymidylate synthase, disrupting DNA synthesis and repair in rapidly dividing cells.
- The oral formulation allows systemic 5-FU exposure without IV infusion.
๐ Indications / Dose
- As per BNF: Used in colorectal cancer, gastric cancer, breast cancer, often in combination regimens.
- Usual dose: 1250 mg/m2 twice daily for 14 days of a 21-day cycle (but always confirm in BNF/chemo protocol).
๐ Interactions
- Refer to BNF for full details.
- Important interactions: warfarin (โ INR/bleeding risk), phenytoin (โ levels), folinic acid (โ toxicity).
โ ๏ธ Cautions
- Renal or hepatic impairment.
- Elderly patients (โ toxicity risk).
- History of severe reactions to fluoropyrimidines.
โ Contraindications
- As per BNF โ absolute contraindications include severe renal impairment (CrCl <30 mL/min), DPD (dihydropyrimidine dehydrogenase) deficiency, pregnancy, and breastfeeding.
โก Side Effects
- Gastrointestinal: diarrhoea, nausea, vomiting, stomatitis.
- Hand-foot syndrome (palmar-plantar erythrodysesthesia): redness, pain, blistering.
- Myelosuppression: neutropenia, anaemia, thrombocytopenia.
- Fatigue, anorexia, mucositis.
- Rare but serious: cardiotoxicity, hepatotoxicity.
๐ References
- BNF โ Capecitabine
- National Cancer Institute โ Capecitabine (Xeloda)
- EMA & FDA prescribing information.